Manifesto & methods
We are living through the long dawn
For three hundred thousand years, a human life was a candle with a fixed length of wick. That is changing. Not in one flash, but the way morning comes: slowly, then everywhere.
Molecules now reach proteins once called undruggable. Immune cells are taught to hunt. Genes are edited inside the living body. Machines read the intention to speak from the surface of a brain. Medicine is being prepared for bodies that will live and work beyond Earth. Science and machine are altering, day by day, what it means to be human, and what a human lifetime can hold.
We believe this is the most important story of the century, and that it deserves a record worthy of it: lofty in vision, exact in fact.
What we promise
- A source for every claim. Each dispatch links the trial record, the journal paper or the regulator's own page.
- The stage on every result. First-in-human signals are never dressed as cures. See The Ascent.
- The unknowns beside the hope. Every entry has a "What we don't know yet" section: side effects, small samples, missing control groups.
- No hype for hire. No sponsored entries, no paid placement, no supplements, no clinic ads, no investment tips.
- No medical advice. We report. Your doctor advises.
How the record is kept
The Long Dawn is an automated, AI-assisted publication with a human owner. Each day a collector reads public sources: the ClinicalTrials.gov API, the WHO International Clinical Trials Registry Platform, regulator announcements (FDA, EMA, Health Canada), major journals (NEJM, The Lancet, JAMA, Nature Medicine, BMJ) and preprint servers. A draft entry is written only after its facts are read on the primary page. A separate review pass tries to reject each draft for overstated claims, missing caveats or wrong numbers before anything is published.
Corrections
If we get something wrong, we fix it and note the change on the entry. Write to thelongdawn@gmail.com or see corrections and contact.
The stars were never the limit. They were the invitation.